Quarterly Period Covered: This 10-Q filing covers the second quarter of fiscal year 2026, ending December 31, 2025 (period from July 1, 2025 to December 31, 2025) Company Information: BIO-TECHNE Corp is a biological products manufacturer (SIC 2836) incorporated in Minnesota with fiscal year ending June 30, headquartered in Minneapolis, MN Financial Statements Included: The filing contains…

Our analysis rates this filing BEARISH. Bio-Techne is facing material operational challenges requiring dual restructuring initiatives focused on margin recovery and manufacturing optimization. The establishment of specific reserve accounts and the appearance of restructuring charges in COGS…

Concern level: HIGH (7.0/10). Key factors: Two parallel restructuring initiatives underway with material reserve accounts established, indicating multi-faceted operational challenges requiring significant remediation; High-severity risks identified: Operating Margins Recovery restructuring (severity 8) and Global Manufacturing Optimization (severity 7), both suggesting competitive or operational…

Notable risk changes: Two distinct restructuring plans disclosed with reserve accounts established - 'Restructuring Plan to Recover Operating Margins' and 'Restructuring Plan to Optimize Global Manufacturing' - indicating management is taking material actions to address operational and margin pressures; Detailed segment reporting reveals geographic concentration (US, UK, China, EMEA) and product concentration…

The model predicts TECH will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.